The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) hit a new 52-week low and has $35.15 target or 6.00% below today’s $37.39 share price. The 5 months bearish chart indicates high risk for the $3.29 billion company. The 1-year low was reported on Oct, 6 by Barchart.com. If the $35.15 price target is reached, the company will be worth $197.40 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 6.36M shares traded hands or 975.52% up from the average. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 17.21% since March 3, 2016 and is uptrending. It has outperformed by 8.86% the S&P500.
Analysts await Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to report earnings on November, 14. They expect $-1.20 EPS, down 31.87% or $0.29 from last year’s $-0.91 per share. After $-1.05 actual EPS reported by Alnylam Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 14.29% negative EPS growth.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Coverage
Out of 12 analysts covering Alnylam Pharmaceuticals (NASDAQ:ALNY), 10 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 83% are positive. $184 is the highest target while $36 is the lowest. The $108.92 average target is 191.31% above today’s ($37.39) stock price. Alnylam Pharmaceuticals has been the topic of 22 analyst reports since August 7, 2015 according to StockzIntelligence Inc. On Friday, August 5 the stock rating was maintained by JP Morgan with “Overweight”. Needham maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Thursday, October 6. Needham has “Buy” rating and $137 price target. The stock has “Hold” rating given by TheStreet on Saturday, August 22. The stock of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) earned “Outperform” rating by JMP Securities on Friday, August 28. Credit Suisse initiated Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Wednesday, January 20. Credit Suisse has “Outperform” rating and $154 price target. The rating was maintained by Piper Jaffray with “Overweight” on Monday, August 31. The firm earned “Outperform” rating on Tuesday, August 11 by FBR Capital. The stock has “Buy” rating given by Chardan Capital Markets on Thursday, October 6. The firm earned “Outperform” rating on Tuesday, February 16 by Leerink Swann. JP Morgan upgraded the shares of ALNY in a report on Friday, March 11 to “Overweight” rating.
According to Zacks Investment Research, “Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.”
Insitutional Activity: The institutional sentiment decreased to 1.27 in 2016 Q2. Its down 0.21, from 1.48 in 2016Q1. The ratio is negative, as 31 funds sold all Alnylam Pharmaceuticals, Inc. shares owned while 60 reduced positions. 23 funds bought stakes while 93 increased positions. They now own 72.84 million shares or 2.29% more from 71.20 million shares in 2016Q1.
D E Shaw And accumulated 39,752 shares or 0% of the stock. Cibc Asset Incorporated has 0% invested in the company for 4,119 shares. Swiss State Bank holds 214,900 shares or 0.02% of its portfolio. Janney Montgomery Scott Lc reported 2,371 shares or 0% of all its holdings. Principal Grp, a Iowa-based fund reported 15,152 shares. Winslow Evans & Crocker accumulated 0% or 1,050 shares. Henderson Gru Public Ltd Company holds 0% or 10,138 shares in its portfolio. Commonwealth Equity Services last reported 5,704 shares in the company. Commerzbank Aktiengesellschaft Fi has invested 0% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Royal London Asset Management Ltd has 0.06% invested in the company for 70,380 shares. Delta Lloyd Nv last reported 0.01% of its portfolio in the stock. The New York-based Timessquare Cap Management Llc has invested 0.07% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Blackrock accumulated 0.01% or 87,265 shares. Evercore Wealth Mgmt Ltd Liability owns 600 shares or 0% of their US portfolio. Schroder Investment Management Gru has 18,592 shares for 0% of their US portfolio.
Insider Transactions: Since April 19, 2016, the stock had 0 insider purchases, and 2 sales for $3.98 million net activity. $1.95M worth of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was sold by MARAGANORE JOHN on Tuesday, July 19.
More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Fool.com which released: “Better Buy: Ziopharm Oncology, Inc. vs. Alnylam Pharmaceuticals, Inc.” on September 24, 2016, also Fool.com with their article: “Better Buy: Alnylam Pharmaceuticals, Inc. vs. Ionis Pharmaceuticals” published on September 02, 2016, Fool.com published: “Alnylam Pharmaceuticals, Inc. Cranks Out the Data” on August 12, 2016. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Fool.com and their article: “Alnylam Pharmaceuticals, Inc.’s Double-Digit “Earnings” Fall” published on May 04, 2016 as well as Fool.com‘s news article titled: “Why Alnylam Pharmaceuticals, Inc. Jumped 10.7% on Friday” with publication date: July 01, 2016.
ALNY Company Profile
Alnylam Pharmaceuticals, Inc., incorporated on May 8, 2003, is a biopharmaceutical company. The Firm is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Firm is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). The Company’s pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.